Revelyx Bio is introducing a new product focused on identifying promising clinical-stage programs and bringing them to global markets.

Revelyx Bio is a clinical-stage biotechnology company advancing APAC innovation into the world’s largest markets. We identify differentiated therapeutic opportunities and scale them through disciplined clinical development, regulatory strategy, and chemistry, manufacturing and controls (CMC). Our initial focus is recombinant botulinum toxin type A (rBoNT/A) for aesthetic and therapeutic indications.